TheraPPI Bioscience SAS

TheraPPI Bioscience SAS is a biotechnology company focused on developing innovative solutions to enhance healthcare and life sciences through advanced biomolecular assays and diagnostic tools. Founded in 2023 in Lyon, France, TheraPPI Bioscience SAS specializes in biotechnology solutions. The company has completed 2 deals, with the most recent deal occurring on February 9, 2025. The founder’s previous entrepreneurial history is not publicly available.

TPPIBIO specializes in the development and commercialization of innovative biotechnology solutions aimed at enhancing various aspects of healthcare and life sciences. Their core product offerings include advanced biomolecular assays and diagnostic tools designed to streamline research processes and improve clinical outcomes. These products address critical needs in disease detection, therapeutic monitoring, and biological research, significantly aiding laboratories and healthcare providers in accurate decision-making. TPPIBIO serves a diverse clientele, including academic institutions, pharmaceutical companies, and healthcare organizations in North America, Europe, and parts of Asia, establishing itself as a key player in the global landscape focused on advancing medical and scientific knowledge.

TPPIBIO generates revenue primarily through a combination of direct sales and B2B partnerships within the biotech sector. The company engages in transactions with its clients through structured agreements, which may include purchase orders for individual diagnostic tools or subscription-based access to their biomolecular assays. These transactions typically involve laboratories and healthcare facilities requiring specialized products for research and clinical applications. With flagship products designed for high-volume usage and specific pricing plans tailored to institutional clients, TPPIBIO's revenue model is built on fostering long-term relationships that promote sustained usage and customer loyalty.

In February 2025, TheraPPI Bioscience SAS raised an undisclosed amount of venture funding from Bpifrance and FONGIT. The company plans to utilize this funding to advance the development of its main program targeting ERK/MyD88. TPPIBIO aims to introduce new products to the market while expanding its presence in additional markets across Europe and Asia by the end of 2026.